Last reviewed · How we verify
voriconazole tablet
At a glance
| Generic name | voriconazole tablet |
|---|---|
| Also known as | Vfend |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study on the Drug Interaction Between Buagafuran and Voriconazole (PHASE1)
- Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects (PHASE1)
- Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections (PHASE2)
- Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes (PHASE1)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
- Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies (PHASE1)
- Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (PHASE1, PHASE2)
- Evaluate Safety and Efficacy of the Coadministration of Ibrexafungerp With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- voriconazole tablet CI brief — competitive landscape report
- voriconazole tablet updates RSS · CI watch RSS
- Pfizer portfolio CI